Wolfgang A. Weber: Publications


Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, Weber WA, Mansi R (2013) Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin. Journal of Nuclear Medicine. Epub ahead of print.

Leonhardt F, Grundmann S, Behe M, Bluhm F, Dumont RA, Braun F, Fani M, Riesner K, Prinz G, Hechinger A-K et al. (2013) Inflammatory neovascularization during graft-versus-host disease is regulated by alphav integrin and miR-100. Blood 121:3307–3318.

Mocharla VP, Walsh JC, Padgett HC, Su H, Fueger B, Weber WA, Czernin J, Kolb HC (2013) From in situ to in vivo: an in situ click-chemistry-derived carbonic anhydrase II imaging agent for positron emission tomography. ChemMedChem 8:43–48.

Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT (2013) 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. Journal of Nuclear Medicine 54:184–191. 


Dobrossy MD, Braun F, Klein S, Garcia J, Langen K-J, Weber WA, Nikkhah G, Meyer PT (2012) [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. Nuclear Medicine and Biology 39:1077–1080.

Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, Spehl TS, Rijntjes M, Hellwig B, Weiller C et al. (2012) [(1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of Parkinsonism. Neurology 79:1314–1322.

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, Reubi JC (2012) Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. Journal of Nuclear Medicine 53:1481–1489.

de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber WA et al. (2012) Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. Journal of Nuclear Medicine 53:701–708.

Fani M, Tamma M-L, Nicolas GP, Lasri E, Medina C, Raynal I, Port M, Weber WA, Maecke HR (2012) In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. Molecular Pharmaceutics 9:1136–1145.

Winz OH, Hellwig S, Mix M, Weber WA, Mottaghy FM, Schafer WM, Meyer PT (2012) Image quality and data quantification in dopamine transporter SPECT: advantage of 3-dimensional OSEM reconstruction? Clinical Nuclear Medicine 37:866–871.

Rischke HC, Benz MR, Wild D, Mix M, Dumont RA, Campbell D, Seufert J, Wiech T, Rossler J, Weber WA et al. (2012) Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. Journal of Nuclear Medicine 53:1352–1358.

Amtage F, Spehl TS, Hellwig S, Sahm U, Hellwig B, Reuland P, Weiller C, Weber WA, Winkler C, Meyer PT (2012) Assessment of striatal dopamine D2/D3 receptor availability with PET and 18F-desmethoxyfallypride: comparison of imaging protocols suited for clinical routine. Journal of Nuclear Medicine 53:1558–1564.

Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC (2012) 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer 118:3135–3144.

Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA et al. (2012) 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clinical Cancer Research 18:2024–2031.


Purz S, Mauz-Korholz C, Korholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O et al. (2011) [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. Journal of Clinical Oncology  29:3523–3528.

Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma M-L, Cescato R, Waser B, Weber WA, Reubi JC, Maecke HR (2011) PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. Journal of Nuclear Medicine 52:1110–1118.

Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M (2011) Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis. Journal of Nuclear Medicine 52:1276–1284.

Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA (2011) Metabolic imaging allows early prediction of response to vandetanib. Journal of Nuclear Medicine 52:231–240.

Czernin J, Weber WA (2011) Issues and controversies in nuclear medicine. Introduction. Journal of Nuclear Medicine 52 Suppl 2:1S–2S.

Weber WA (2011) Is there evidence for evidence-based medical imaging? Journal of Nuclear Medicine 52 Suppl 2:74S–76S.

Behe M, Alt K, Deininger F, Buhler P, Wetterauer U, Weber WA, Elsasser-Beile U, Wolf P (2011) In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo (Athens, Greece) 25:55–59.

Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brandle M, Seufert J, Weber WA, Bomanji J, Perren A et al. (2011) Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. Journal of Nuclear Medicine 52:1073–1078.

Vach W, Hoilund-Carlsen PF, Gerke O, Weber WA (2011) Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. Journal of Nuclear Medicine 52 Suppl 2:77S–85S.

Wild D, Fani M, Behe M, Brink I, Rivier JEF, Reubi JC, Maecke HR, Weber WA (2011) First clinical evidence that imaging with somatostatin receptor antagonists is feasible. Journal of Nuclear Medicine 52:1412–1417.

Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, Weber WA, Hull M (2011) Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. Journal of Nuclear Medicine 52:393–400.

Grosu A-L, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester H-J, Weber WA (2011) An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. International Journal of Radiation Oncology, Biology, Physics 81:1049–1058.

Heidt T, Deininger F, Peter K, Goldschmidt J, Pethe A, Hagemeyer CE, Neudorfer I, Zirlik A, Weber WA, Bode C et al. (2011) Activated platelets in carotid artery thrombosis in mice can be selectively targeted with a radiolabeled single-chain antibody. PloS One 6:e18446.

Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS (2011) (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. Journal of Nuclear Medicine 52:1684–1689.


Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, Phelps ME, Czernin J, Weber WA, Schiestl RH (2010) Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. Journal of Nuclear Medicine 51:1285–1292.

Aweda TA, Beck HE, Wu AM, Wei LH, Weber WA, Meares CF (2010) Rates and equilibria for probe capture by an antibody with infinite affinity. Bioconjugate Chemistry 21:784–791.

Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC (2010) Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116:451–458.

Weber WA (2010) Quantitative analysis of PET studies. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 96:308–310.

Grosu AL, Weber WA (2010) PET for radiation treatment planning of brain tumours. Radiotherapy and Oncology 96:325–327.

Weber WA (2010) Monitoring tumor response to therapy with 18F-FLT PET. Journal of Nuclear Medicine 51:841–844.

Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC (2010) FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma 2010:143540.

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJG, Kotzerke J, Hoekstra OS, Pruim J et al. (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging 37:181–200.


Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA (2009) Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Research 69:3173–3179.

Allen-Auerbach M, Weber WA (2009) Measuring response with FDG-PET: methodological aspects. The Oncologist 14:369–377.

Grosu A-L, Nestle U, Weber WA (2009) How to use functional imaging information for radiotherapy planning. European Journal of Cancer (Oxford, UK) 45 Suppl 1:461–463.

Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME et al. (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clinical Cancer Research 15:2856–2863.

Ferl GZ, Dumont RA, Hildebrandt IJ, Armijo A, Haubner R, Reischl G, Su H, Weber WA, Huang S-C (2009) Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. Journal of Nuclear Medicine 50:250–258.

Weber WA (2009) Assessing tumor response to therapy. Journal of Nuclear Medicine 50 Suppl 1:1S–10S.


Plathow C, Weber WA (2008) Tumor cell metabolism imaging. Journal of Nuclear Medicine 49 Suppl 2:43S–63S.

Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA (2008) Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. Journal of Nuclear Medicine 49:1038–1046.

Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA et al. (2008) TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13:507–518.

Weber WA, Czernin J, Phelps ME, Herschman HR (2008) Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nature Clinical Practice Oncology 5:44–54.

Weber WA, Grosu AL, Czernin J (2008) Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nature Clinical Practice Oncology 5:160–170.

Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME et al. (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clinical Cancer Research14:715–720.

Buerkle A, Weber WA (2008) Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Reviews 27:545–554.

Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu Y-T, Dubinett SM, Phelps ME, Czernin J et al. (2008) Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. European Journal of Nuclear Medicine and Molecular Imaging 35:1089–1099.

Lordick F, Ruers T, Aust DE, Collette L, Downey RJ, El Hajjam M, Flamen P, Haustermans K, Ilson D, Julie C et al. (2008) European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. European Journal of Cancer (Oxford, England) 44:1807–1819.

Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA (2008) Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. Journal of Nuclear Medicine 49:1828–1835.

Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, Molls M, Weber WA, Grosu A-L (2008) Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. International Journal of Radiation Oncology, Biology, Physics 72:1161–1167.

Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K et al. (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clinical Cancer Research 14:2012–2018.

Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJJ, Dry S, Phelps ME, Czernin J, Weber WA (2008) Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. Journal of Nuclear Medicine 49:1579–1584.

Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA (2008) Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clinical Cancer Research 14:3416–3426.

Hildebrandt IJ, Su H, Weber WA (2008) Anesthesia and other considerations for in vivo imaging of small animals. ILAR Journal 49:17–26.

Brown RH, Irvin CG, Allen GBr, Shapiro SD, Martin WJ, Kolb MRJ, Hyde DM, Nieman GF, Cody DD, Ishii M et al. (2008) An official ATS conference proceedings: advances in small-animal imaging application to lung pathophysiology. Proceedings of the American Thoracic Society 5:591–600.


Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A et al. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology 25:571–578.

Kneilling M, Hultner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, Eichner M, Sabatino J, Biedermann T, Krenn V et al. (2007) Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis and Rheumatism 56:1806–1816.

Weber WA, Czernin J, Phelps ME (2007) Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture? Clinical Cancer Research 13:3105–3106.

Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA (2007) Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. European Journal of Nuclear Medicine and Molecular Imaging 34:1925–1932.

Lordick F, Ott K, Krause B-J, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. The Lancet Oncology 8:797–805.

Weber WA, Figlin R (2007) Monitoring cancer treatment with PET/CT: does it make a difference? Journal of Nuclear Medicine 48 Suppl 1:36S–44S.

Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M (2007) Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Annals of Surgery 246:624–8- discussion 628-31.

Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proceedings of the National Academy of Sciences of the United States of America 104:15549–15554.

Nieder C, Cai L, Weber WA, Schill S, Andratschke N, Schwaiger M, Molls M (2007) Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity. Anticancer Research 27:183–187.

Nieder C, Schnaiter A, Weber WA, Schill S, Andratschke N, Schwaiger M, Molls M (2007) Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation. Anticancer Research 27:2353–2357.

Weber WA (2007) 18F-FDG PET in non-Hodgkin’s lymphoma: qualitative or quantitative? Journal of Nuclear Medicine 48:1580–1582.


Andratschke N, Schnaiter A, Weber WA, Cai L, Schill S, Wiedenmann N, Schwaiger M, Molls M, Nieder C (2006) Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. International Journal of Radiation Oncology, Biology, Physics 64:1513–1518.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu A-L, Schnell O, Niemeyer M, Kessler H, Wester H-J et al. (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clinical Cancer Research 12:3942–3949.

Weber WA (2006) Positron emission tomography as an imaging biomarker. Journal of Clinical Oncology 24:3282–3292.

Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, Grosu A-L, Martinez M-J, Wester H-J, Weber WA et al. (2006) PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. Journal of Nuclear Medicine 47:763–769.

Weber WA, Wieder H (2006) Monitoring chemotherapy and radiotherapy of solid tumors. European Journal of Nuclear Medicine and Molecular Imaging 33 Suppl 1:27–37.

Czernin J, Weber WA, Herschman HR (2006) Molecular imaging in the development of cancer therapeutics. Annual Review of Medicine 57:99–118.

Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. Journal of Clinical Oncology 24:4692–4698.

Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. Journal of Nuclear Medicine 47:999–1006.

Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA (2006) Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 129:393–401.

Weber WA (2006) Chaperoning drug development with PET. Journal of Nuclear Medicine 47:735–737.

Grosu A-L, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, Molls M, Nieder C (2006) 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. International Journal of Radiation Oncology, Biology, Physics 66:339–344.


Weber WA (2005) Use of PET for monitoring cancer therapy and for predicting outcome. Journal of Nuclear Medicine 46:983–995.

Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. International Journal of Radiation Oncology, Biology, Physics 63:511–519.

Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, Czernin J (2005) Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128:2289–2297.

Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W (2005) Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. Journal of Clinical Oncology 23:7445–7453.

Grosu A-L, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M (2005) Positron emission tomography for radiation treatment planning. Strahlentherapie und Onkologie 181:483–499.

Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J (2005) Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Molecular Imaging and Biology 7:369–376.

Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, Silverman DHS, Ratib O, Czernin J (2005) Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. Journal of Nuclear Medicine 46:603–607.

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker K-F, Goebel M, Hein R, Wester H-J et al. (2005) Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Medicine 2:e70.

Avril NE, Weber WA (2005) Monitoring response to treatment in patients utilizing PET. Radiologic Clinics of North America 43:189–204.

Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J et al. (2005) Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3’-deoxy-3’-18F-fluorothymidine PET. Journal of Nuclear Medicine 46:114–120.

Grosu A-L, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, Gumprecht H, Jaeger R, Schwaiger M, Molls M (2005) L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. International Journal of Radiation Oncology, Biology, Physics 63:64–74.

Pichler BJ, Kneilling M, Haubner R, Braumuller H, Schwaiger M, Rocken M, Weber WA (2005) Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. Journal of Nuclear Medicine 46:184–189.

Wieder HA, Beer AJ, Lordick F, Ott K, Fischer M, Rummeny EJ, Ziegler S, Siewer JR, Schwaiger M, Weber WA (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. Journal of Nuclear Medicine 46:2029–2034.

Kim J-H, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA (2005) Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. Journal of Nuclear Medicine 46:587–595.

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester H-J, Weber WA, Schwaiger M (2005) Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. Journal of Nuclear Medicine 46:1333–1341.


Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester H-J, Schwaiger M (2004) [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chemistry 15:61–69.

Anton M, Wagner B, Haubner R, Bodenstein C, Essien BE, Bonisch H, Schwaiger M, Gansbacher B, Weber WA (2004) Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. The Journal of Gene Medicine 6:119–126.

Wieder HA, Brucher BLDM, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ et al. (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. Journal of Clinical Oncology 22:900–908.

Weber WA, Ott K (2004) Imaging of esophageal and gastric cancer. Seminars in Oncology 31:530–541.

Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DHS, Ratib O, Phelps ME, Czernin J (2004) Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Molecular Imaging and Biology 6:411–416.

Weber WA (2004) Brown adipose tissue and nuclear medicine imaging. Journal of Nuclear Medicine 45:1101–1103.

2003 and Earlier

Grosu A-L, Lachner R, Wiedenmann N, Stark S, Thamm R, Kneschaurek P, Schwaiger M, Molls M, Weber WA (2003) Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. International Journal of Radiation Oncology, Biology, Physics 56:1450–1463.

Ott K, Fink U, Becker K, Stahl A, Dittler H-J, Busch R, Stein H, Lordick F, Link T, Schwaiger M et al. (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. Journal of Clinical Oncology 21:4604–4610.

Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. Journal of Clinical Oncology 21:2651–2657.

Ott K, Weber WA, Fink U, Helmberger H, Becker K, Stein HJ, Muller J, Schwaiger M, Siewert JR (2003) Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World Journal of Surgery 27:1035–1039.

Rau FC, Weber WA, Wester H-J, Herz M, Becker I, Kruger A, Schwaiger M, Senekowitsch-Schmidtke R (2002) O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging 29:1039–1046.

Avril N, Schelling M, Dose J, Weber WA, Schwaiger M (1999) Utility of PET in Breast Cancer. Clinical Positron Imaging 2:261–271.